The Arecor stabilisation technology originated from the need to sterilise an active ingredient, glucose oxidase, using ionising radiation. The novel chemical concepts that were discovered were then built upon to protect this active ingredient during long term storage. The transition of these concepts from a medical device to biologics was confirmed, which then lead to a new field of stabilisation ideas and concepts.

Today the Arecor stabilising technology can be applied to the biopharmaceutical and diagnostic sector offering protection to biologics against degradation during long term storage and damage caused by exposure to ionising radiation typically used in sterilisation.

Arecor has substantially expanded the protein stabilisation technology and successfully applied it to a wide range of biopharmaceuticals, medical devices and diagnostics, building significant partnerships with a number of major pharmaceutical and biotechnology companies.

Arecor is based at Cambridge Science Park in the United Kingdom and employs staff with expertise in protein formulation and analysis, manufacture and regulatory approval. It has extensive in-house analytical capabilities and access to the facilities of Unilever Research and Cambridge University.

Arecor is a spin out of Unilever Research and Unilever Ventures is our lead investor.